EVO LABS

Human Performance is a critical field studied by the sports and pharmaceutical industries. While the needs of the global sports market grow, the available solutions lack clarity, validation, personalization, and precision. The World of Sports has been popular for decades. Yet, the rise in popularity comes with the rise of challenges and adversity. Regarding the future, the sports industry is already faced with the challenge of trying to predict the next trend, the next big idea that will capture the audience by creating a future of personalised medicine, where Engineering solutions defend causality of abnormalities in the Human system. Coupling this challenge with that of technology, it is clear that several sports teams and medical/performance experts will always be at odds. With muscle capability being known, overcoming personal boundaries becomes the principal problem for human performance.

EVO Labs introduces a “must-have” tool for every sports club and every athlete, based on BioEngineering principles, enriching decision-making and human performance for the individual’s mechanical ability. The company provides an optimal sports performance technology through personalised performance capacity and injury prevention. It implements a complete data processing pipeline, combining the engineering and the medical domains, and offers personalised actionable myoskeletal performance guidance. A new era of engineering and medicine collaboration begins, delivering an optimal solution for the human body. Our mission is to help athletes at international level increase their performance and classification, through minimising rehabilitation periods—thus securing the viability of sports clubs and improving the sports spectacle. Using our technology, we support sport clubs and athletes to achieve excellence and maintain their top performance over time.

One of the leading causes of death globally are cardiovascular diseases. While the most important behavioural risk factors are currently known, there are also a number of underlying determinants. Therefore, readily available state-of-the-art risk models lack personalization and precision. It has become increasingly clear that inflammation also plays a pivotal role in the development of atherosclerosis and cardiovascular disease (CVD). The biological processes involved in atherogenesis are highly complex and only partially understood.

C-reactive protein (CRP), measured with a highly sensitive assay, is the most frequently used marker of low levels of inflammation and has been associated with increased risk of CVD, as well as the presence of risk factors including adiposity. Furthermore, CRP is used as an adjunct for risk assessment in conjunction with the Framingham Risk Score (FRS). In addition, the inclusion of cardiovascular disease management interventions in universal health coverage packages requires significant investment and reorientation to effectively manage CVDs.

EVO Lab introduces a “must-have” tool, based on new biomarkers and implementing a competing risk model, which enables better estimation of the risk in both younger and older populations. The company provides an optimal CVD prognosis technology through personalised treatment for patients and early identification for youngsters. It implements a complete data processing pipeline, combining the engineering and the medical domains, and offers personalised risk management. A new era of engineering and medicine collaboration begins, delivering an optimal solution for the human body.

The essence of particle transport in the respiratory system is well known. Harmful substances such as dust, fumes, and gaseous pollutants are widely suspended in the environment and can either cause immediate minor disorders like dizziness or serious long-term damage such as asthma or cancer. In many chronic lung disease cases, prescribing effective treatment is crucial. Studying particle transport provides both diagnostic and preventative insight into adverse respiratory health conditions.

EVO Labs embraces this challenge by leveraging Computational Fluid Dynamics (CFD) combined with particle dynamics simulations. This approach helps explore two key questions: the fate of each particle entering the respiratory system, and the optimal spatial and temporal points for particle release to reach a specific location. Using this methodology, a wide range of respiratory issues can be studied while minimizing costs and setup complexity.

Our goal is to build modern, optimized CFD simulations based on realistic tissue geometries to better understand the mechanisms behind respiratory system damage—whether caused by toxic exposure or conditions like COVID-19. This deeper insight enables early threat prediction and investigation of various exposure scenarios under different boundary conditions. A robust, cost-effective approach like this paves the way for the future of respiratory prevention and treatment.

Finite Element Analysis (FEA) is a very powerful technique when it comes to biomechanics in the broad area of orthopaedics. It proves to be an effective and precise tool to fully understand, accurately predict, and prevent mechanically related failures. When combined with biomechanics, it provides a comprehensive way to analyze the physical mechanisms governing the human body.

At EVO Labs, a promising application is in development: a simulation of knee biomechanics including the medial meniscus. Through FEA simulation, we can extract results showing total deformation in different cases, helping to identify the areas of the meniscus most prone to stress and potential failure. This method can also be applied to other anatomical structures in the model. Ultimately, our project aims to support a Personalised Bioengineering Assessment of tendons, bones, and ligaments.